Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:19948979rdf:typepubmed:Citationlld:pubmed
pubmed-article:19948979lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:19948979lifeskim:mentionsumls-concept:C0021368lld:lifeskim
pubmed-article:19948979lifeskim:mentionsumls-concept:C1706515lld:lifeskim
pubmed-article:19948979lifeskim:mentionsumls-concept:C0004153lld:lifeskim
pubmed-article:19948979lifeskim:mentionsumls-concept:C0754728lld:lifeskim
pubmed-article:19948979lifeskim:mentionsumls-concept:C1704640lld:lifeskim
pubmed-article:19948979lifeskim:mentionsumls-concept:C0699900lld:lifeskim
pubmed-article:19948979lifeskim:mentionsumls-concept:C0243125lld:lifeskim
pubmed-article:19948979lifeskim:mentionsumls-concept:C0086597lld:lifeskim
pubmed-article:19948979lifeskim:mentionsumls-concept:C0331858lld:lifeskim
pubmed-article:19948979pubmed:issue24lld:pubmed
pubmed-article:19948979pubmed:dateCreated2009-12-16lld:pubmed
pubmed-article:19948979pubmed:abstractTextInflammation and matrix degradation are the hallmarks of high-risk atherosclerosis that leads to myocardial infarction and stroke. Toll-like receptors (TLRs), key players in innate immunity, are upregulated in atherosclerotic lesions, but their functional role in human atherosclerosis is unknown. We explored the effects of blocking TLR-2, TLR-4, and myeloid differentiation primary response gene 88 (MyD88), a signaling adaptor shared by most TLRs and interleukin-1 receptor (IL-1R), in an in vitro model of human atherosclerosis.lld:pubmed
pubmed-article:19948979pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19948979pubmed:languageenglld:pubmed
pubmed-article:19948979pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19948979pubmed:citationSubsetAIMlld:pubmed
pubmed-article:19948979pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19948979pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19948979pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19948979pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19948979pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19948979pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19948979pubmed:statusMEDLINElld:pubmed
pubmed-article:19948979pubmed:monthDeclld:pubmed
pubmed-article:19948979pubmed:issn1524-4539lld:pubmed
pubmed-article:19948979pubmed:authorpubmed-author:DaviesAlun...lld:pubmed
pubmed-article:19948979pubmed:authorpubmed-author:FoxwellBrian...lld:pubmed
pubmed-article:19948979pubmed:authorpubmed-author:FeldmannMarcMlld:pubmed
pubmed-article:19948979pubmed:authorpubmed-author:MonacoClaudia...lld:pubmed
pubmed-article:19948979pubmed:authorpubmed-author:GreganScott...lld:pubmed
pubmed-article:19948979pubmed:authorpubmed-author:NavinTina JTJlld:pubmed
pubmed-article:19948979pubmed:issnTypeElectroniclld:pubmed
pubmed-article:19948979pubmed:day15lld:pubmed
pubmed-article:19948979pubmed:volume120lld:pubmed
pubmed-article:19948979pubmed:ownerNLMlld:pubmed
pubmed-article:19948979pubmed:authorsCompleteYlld:pubmed
pubmed-article:19948979pubmed:pagination2462-9lld:pubmed
pubmed-article:19948979pubmed:meshHeadingpubmed-meshheading:19948979...lld:pubmed
pubmed-article:19948979pubmed:meshHeadingpubmed-meshheading:19948979...lld:pubmed
pubmed-article:19948979pubmed:meshHeadingpubmed-meshheading:19948979...lld:pubmed
pubmed-article:19948979pubmed:meshHeadingpubmed-meshheading:19948979...lld:pubmed
pubmed-article:19948979pubmed:meshHeadingpubmed-meshheading:19948979...lld:pubmed
pubmed-article:19948979pubmed:meshHeadingpubmed-meshheading:19948979...lld:pubmed
pubmed-article:19948979pubmed:meshHeadingpubmed-meshheading:19948979...lld:pubmed
pubmed-article:19948979pubmed:meshHeadingpubmed-meshheading:19948979...lld:pubmed
pubmed-article:19948979pubmed:meshHeadingpubmed-meshheading:19948979...lld:pubmed
pubmed-article:19948979pubmed:meshHeadingpubmed-meshheading:19948979...lld:pubmed
pubmed-article:19948979pubmed:meshHeadingpubmed-meshheading:19948979...lld:pubmed
pubmed-article:19948979pubmed:year2009lld:pubmed
pubmed-article:19948979pubmed:articleTitleToll-like receptor-2 mediates inflammation and matrix degradation in human atherosclerosis.lld:pubmed
pubmed-article:19948979pubmed:affiliationKennedy Institute of Rheumatology Division, Imperial College, 65 Aspenlea Rd, London W6 8LH, UK. c.monaco@imperial.ac.uklld:pubmed
pubmed-article:19948979pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:19948979pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:19948979pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
entrez-gene:7097entrezgene:pubmedpubmed-article:19948979lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:19948979lld:entrezgene
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:19948979lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:19948979lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:19948979lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:19948979lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:19948979lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:19948979lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:19948979lld:pubmed